FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895852226> ?p ?o ?g. }

• W2895852226 endingPage "340" @default.
• W2895852226 startingPage "329" @default.
• W2895852226 abstract "Peyronie's disease (PD) is a fibrotic disorder of the penile tunica albuginea, characterised by the formation of a localised fibrous plaque that can lead to deformity and erectile dysfunction. Nonsurgical therapeutic options for PD are limited in efficacy and safety. Myofibroblasts are key cells in the pathogenesis of PD, and inhibition of myofibroblast transformation has been suggested as a therapeutic option. To identify potential drugs using a novel phenotypic assay and then to test them using in vitro and in vivo models of PD. We have developed and validated a phenotypic screening assay that measures myofibroblast transformation, by which we tested 21 compounds that were suggested to be efficacious in treating PD. The successful hits from this assay were further tested using in vitro and in vivo models of PD. The new assay was able to detect transforming growth factor-β1–induced myofibroblast transformation. Using this assay, phosphodiesterase type 5 inhibitors (PDE5i) and selective oestrogen receptor modulators (SERMs) were identified to significantly inhibit myofibroblast transformation. A PDE5i (vardenafil) and an SERM (tamoxifen) inhibited myofibroblast transformation, collagen gel contraction, and extracellular matrix production in a synergistic fashion. In a rat model of PD, the antifibrotic effect of the combination of vardenafil and tamoxifen was greater than that of each drug alone. This study is limited by not providing a molecular mechanism for the proposed synergy. This is the first demonstration of a synergistic activity between a PDE5i and an SERM discovered through a phenotypic screening approach. Future clinical trials using a combination of these drugs should be considered during the active phase of PD, given the early evidence of benefit in both in vitro and in vivo models. This report suggests that the combination of a phosphodiesterase type 5 inhibitor and a selective oestrogen receptor modulator may be efficacious in treating Peyronie's disease in its active phase." @default.
• W2895852226 created "2018-10-26" @default.
• W2895852226 creator A5016275908 @default.
• W2895852226 creator A5016630344 @default.
• W2895852226 creator A5017136849 @default.
• W2895852226 creator A5045209885 @default.
• W2895852226 creator A5045733440 @default.
• W2895852226 creator A5048757703 @default.
• W2895852226 creator A5053197241 @default.
• W2895852226 creator A5085174316 @default.
• W2895852226 creator A5088974834 @default.
• W2895852226 date "2019-02-01" @default.
• W2895852226 modified "2023-09-26" @default.
• W2895852226 title "Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models" @default.
• W2895852226 cites W1502525967 @default.
• W2895852226 cites W1505584712 @default.
• W2895852226 cites W1533497429 @default.
• W2895852226 cites W1569726736 @default.
• W2895852226 cites W1847662742 @default.
• W2895852226 cites W1867225876 @default.
• W2895852226 cites W1892675218 @default.
• W2895852226 cites W1963875557 @default.
• W2895852226 cites W1968672070 @default.
• W2895852226 cites W1980193533 @default.
• W2895852226 cites W1984729535 @default.
• W2895852226 cites W1995421159 @default.
• W2895852226 cites W2006926974 @default.
• W2895852226 cites W2012134317 @default.
• W2895852226 cites W2024834003 @default.
• W2895852226 cites W2034591737 @default.
• W2895852226 cites W2042270638 @default.
• W2895852226 cites W2043449217 @default.
• W2895852226 cites W2049458875 @default.
• W2895852226 cites W2050184976 @default.
• W2895852226 cites W2050398117 @default.
• W2895852226 cites W2062052817 @default.
• W2895852226 cites W2068127169 @default.
• W2895852226 cites W2086154979 @default.
• W2895852226 cites W2086292474 @default.
• W2895852226 cites W2089740836 @default.
• W2895852226 cites W2090503365 @default.
• W2895852226 cites W2091598416 @default.
• W2895852226 cites W2093416901 @default.
• W2895852226 cites W2114222033 @default.
• W2895852226 cites W2116902092 @default.
• W2895852226 cites W2124991789 @default.
• W2895852226 cites W2134169166 @default.
• W2895852226 cites W2140850097 @default.
• W2895852226 cites W2346758169 @default.
• W2895852226 cites W2607291703 @default.
• W2895852226 cites W2742862090 @default.
• W2895852226 cites W2805295970 @default.
• W2895852226 cites W4319308458 @default.
• W2895852226 doi "https://doi.org/10.1016/j.eururo.2018.10.014" @default.
• W2895852226 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30344087" @default.
• W2895852226 hasPublicationYear "2019" @default.
• W2895852226 type Work @default.
• W2895852226 sameAs 2895852226 @default.
• W2895852226 citedByCount "29" @default.
• W2895852226 countsByYear W28958522262019 @default.
• W2895852226 countsByYear W28958522262020 @default.
• W2895852226 countsByYear W28958522262021 @default.
• W2895852226 countsByYear W28958522262022 @default.
• W2895852226 countsByYear W28958522262023 @default.
• W2895852226 crossrefType "journal-article" @default.
• W2895852226 hasAuthorship W2895852226A5016275908 @default.
• W2895852226 hasAuthorship W2895852226A5016630344 @default.
• W2895852226 hasAuthorship W2895852226A5017136849 @default.
• W2895852226 hasAuthorship W2895852226A5045209885 @default.
• W2895852226 hasAuthorship W2895852226A5045733440 @default.
• W2895852226 hasAuthorship W2895852226A5048757703 @default.
• W2895852226 hasAuthorship W2895852226A5053197241 @default.
• W2895852226 hasAuthorship W2895852226A5085174316 @default.
• W2895852226 hasAuthorship W2895852226A5088974834 @default.
• W2895852226 hasBestOaLocation W28958522261 @default.
• W2895852226 hasConcept C121608353 @default.
• W2895852226 hasConcept C126322002 @default.
• W2895852226 hasConcept C142724271 @default.
• W2895852226 hasConcept C150903083 @default.
• W2895852226 hasConcept C207001950 @default.
• W2895852226 hasConcept C207865475 @default.
• W2895852226 hasConcept C2777176818 @default.
• W2895852226 hasConcept C2777944059 @default.
• W2895852226 hasConcept C2778822586 @default.
• W2895852226 hasConcept C2779145901 @default.
• W2895852226 hasConcept C2779929075 @default.
• W2895852226 hasConcept C2780559512 @default.
• W2895852226 hasConcept C2780816001 @default.
• W2895852226 hasConcept C502942594 @default.
• W2895852226 hasConcept C530470458 @default.
• W2895852226 hasConcept C71924100 @default.
• W2895852226 hasConcept C86803240 @default.
• W2895852226 hasConcept C98274493 @default.
• W2895852226 hasConceptScore W2895852226C121608353 @default.
• W2895852226 hasConceptScore W2895852226C126322002 @default.
• W2895852226 hasConceptScore W2895852226C142724271 @default.
• W2895852226 hasConceptScore W2895852226C150903083 @default.
• W2895852226 hasConceptScore W2895852226C207001950 @default.

• next